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A century of traditional vaccinology lost the fight against menin-
gococcus serogroup B (MenB). However, thanks to an innovative 
genome-based approach, the first broadly effective MenB vaccine, 
Bexsero® (GSK Vaccines), was developed and has been licensed for 
use in various age groups by the European Commission and other 
regulatory authorities. Genes encoding for the main meningococcus 
B antigens were identified and screened in order to achieve a broadly 
protective vaccine, taking into account the fact that meningococcus 
B has many different subtypes whose membrane proteins may be dif-
ferent. Since the antigens selected for Bexsero® are also harbored 
by meningococci belonging to other serogroups there may be the 
potential for Bexsero® to offer a certain level of protection against 
non-B serogroups. Therefore preliminary studies were carried out 
to investigate the potential of the vaccine to also provide a degree 
of cross protection against non-B serogroups. Here we review the 
potential for Bexsero® to offer a certain level of protection against 
the diversity of meningococcus type B subtypes and its potential abil-
ity to offer some cross protection from non-B serogroups. Lastly, we 
describe the future perspectives in pentavalent meningococcal vac-
cine (ABCWY) development which hopefully will result in a vaccine 
able to help prevent Invasive Meningococcal Diseases (IMD) from 
the majority of currently circulating meningococcal strains. 
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Summary
Introduction
Two centuries of meningococcal infection have ‘pushed’ 
the scientific and medical community to search for vac-
cines in order to harness the ingenious and almost infi-
nite and dynamic survival/infective strategies of menin-
gococci: from live-attenuated vaccines (1900) to subunit 
polysaccharide vaccines (1970) to glyconjugated vac-
cines (1990) to OMV vaccines, to quadrivalent vaccines 
ACWY (2003) and most recently to reverse vaccinology 
and the licensure of Bexsero® in the EU for individuals 
above the age of 2 months on 14 January 2013.
At the beginning of the twentieth century, the majority 
of bacterial meningitis in children was caused by Hae-
mophilus influenzae type b, pneumococcus, and menin-
gococcus. Available vaccines for the first two bacteria 
have led to a dramatic incidence reduction of the disease 
leaving N. meningitidis as the major cause of bacterial 
meningitis worldwide [1-3].
Considering the panel of meningococcal vaccines now 
available, the prevention of serogroup B-related IMD placed 
unique challenges in the development of a MenB vaccine: 
firstly, the inability to use the Men B capsule because its 
structure resembles a self-antigen and secondly the high 
variability of the antigenic membrane protein mix [3, 4]. 
Glycoconjugate vaccines against serogroups A, C, W, 
and Y exploit the antigenicity of the capsular polysac-
charides that characterize each one of the four sero-
groups: however, for MenB this approach was not feasi-
ble due to the similarity of the capsule to a self-antigen; 
if used in a vaccine the capsular polysaccharide would 
be very poorly immunogenic [3]. 
An alternative approach was devised when Outer Mem-
brane Vesicles (OMVs) were successfully used to control 
specific outbreaks. OMVs are proteoliposomes that contain 
several different molecular moieties, out of which the porin 
protein, PorA, is the principle antigenic source of bacteri-
cidal antibodies. The limitations of these vaccines are well 
recognized: effectiveness tends to be limited to strains 
containing the same PorA protein (serosubtype-specific), 
limiting its use to strain-specific outbreaks [5]. Thus, ad-
vancements toward MenB IMD protection using OMPs 
(Outer Membrane Proteins) were limited, since multivalent 
OMPs-based vaccines may not be effective in preventing 
the majority of endemic disease. Indeed data from Tondella 
et al. showed that a large number of serosubtypes (20 or 
more) might have to be included in a multivalent OMPs-
based vaccine to target 80% of sporadic disease caused by 
meningococcus B in US [6].
Therefore, due to the inability to use either the capsule or 
the OMVs, MenB vaccine development was significantly 
impaired. The challenge was to develop a MenB vaccine 
demonstrated to have acceptable safety and immuno-
genicity profiles in all age groups, particularly in infants, 
who represent the major group at risk of IMD, and able to 
induce immunity against the majority of circulating sero-
subtypes [4]. An innovative genome based approach was 
then devised, so to identify genes encoding for the main 
Men B antigens. These antigens were screened to select 
molecules possessing a good immunogenicity and being 
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surface exposed. Once the candidate antigens were final-
ly selected, a four component formulation was tested in 
clinical trials, showing a good immunogenicity and safety 
profile for the developmental vaccine [7]. 
The four main components of Bexsero® have a major 
role for the virulence of N. meningitidis, from adherence 
to colonization of the nasopharynx, to survival in blood 
stream and cerebrospinal fluid. The first component, 
factor H binding protein (fHbp), fused with GNA2091 
protein, binds human factor H on its surface; once the 
bacteria is “covered” with factor H it can evade the host 
immune response by mimicking a self-antigen. The 
second component, NadA, is a major adhesion protein 
involved in colonization, invasion, and induction of pro-
inflammatory cytokines. The third component, NHBA, 
is a heparin-binding protein that increases resistance 
against the bactericidal activity of human serum and is 
virtually present in all strains. NHBA is fused with pro-
tein GNA1030. The fourth antigen, OMV NZ98/254, 
has several antigenic components the major of which 
is PorA, and has successfully demonstrated tolerability 
and effectiveness when used to help control the New 
Zealand serogroup B outbreak [8].
The resulting vaccine, Bexsero® was the first broad-cov-
erage MenB vaccine based on recombinant proteins ap-
proved for use in individuals 2 months of age and above 
by the European Commission in January 2013, and was ap-
proved for use in individuals from 10 to 25 years of age by 
the US FDA in January 2015. Bexsero® has also been ap-
proved for use in individuals of varying ages in Australia, 
Canada, Brazil and Uruguay among other countries [9, 10].
A further analysis was needed in order to predict the abili-
ty of the vaccine to be broadly protective against a variety 
of Men B subtypes: therefore a specific Meningococcal 
Antigen Typing System was devised (MATS) [9].
According to conventional genotyping and other pre-
liminary studies the antigens contained in Bexsero® 
are not only pan genomic, i.e. present in the majority 
of circulating serogroup B strains, but in addition are 
evolutionarily conserved in the meningococcal popu-
lation leading to the fact that Bexsero® may also offer 
a certain level of protection against non-B serogroups 
meningococci [8, 11-13].
The Meningococcal Antigen Typing 
System: MATS 
Since the 1960s immunogenicity of meningococcal vac-
cines has been evaluated by means of complement-medi-
ated killing of bacteria in the serum bactericidal antibody 
assay with human complement (hSBA) [14-17]. Howev-
er, since protein antigens may vary in their presence, se-
quence and level of expression, evaluating the effective-
ness of protein-based vaccines such as Bexsero® would 
require testing many different meningococcal subtype 
strains directly in hSBA, an impractical undertaking 
especially when the tests are done for infants, because 
serum volumes are very limited [5]. Due to frequent re-
combination in the MenB subtypes genotyping-based 
methods such as multilocus sequence typing are not suit-
able either [18, 19]. An alternative means of measuring 
the presence of surface-based antigens was needed and 
the Meningococcal Antigen Typing System (MATS) 
was developed to meet that need [9]. 
MATS evaluates the degree to which circulating sero-
group B strains express each of the vaccine antigens, 
fHbp, NadA, NHBA, and PorA1.4, and helps determine 
the probability that strains will be killed in hSBA by an-
tibodies obtained from individuals immunized with Bex-
sero® [20, 21]. Positive results in this type of test (MATS) 
are obtained if antigens are: (1) expressed to a sufficient 
degree; and (2) similar enough in terms of structure and 
sequence to the antigens in the vaccine so that the anti-
bodies generated by Bexsero® will kill the bacteria. Good 
expression of at least one Bexsero® antigen is sufficient 
for a strain to be killed. MATS has been validated and 
standardized and is used by national reference laborato-
ries around the globe to estimate the predictive effective-
ness of Bexsero®. MATS has already been used to esti-
mate strain coverage in the following countries: Australia, 
Brazil, Canada, Czech Republic, England and Wales, 
France, Germany, Greece, Italy, Norway, Spain, and the 
United States, with predicted coverage ranging from 66% 
in Canada (95% CI, 43–78%) to 91% in US (95% CI, 
72–96%) [8]. In particular Vogel and colleagues assessed 
all MenB isolates from 5 European countries that were 
submitted to reference laboratories over a full epidemio-
logical year from July 2007 to June 2008 [20]. Overall, 
1052 MenB strains were collected in England and Wales 
(n = 535), France (n = 200), Germany (n = 222), Italy (n = 
54), and Norway (n = 41). The predicted Bexsero® cover-
age in individual countries ranged from 73% (95% CI, 57-
87%) in England and Wales to 87% (95% CI, 70-93%) in 
Italy. Importantly, 50% of all strains and 64% of covered 
strains could be targeted by antibodies against more than 
one Bexsero® antigen, thus ensuring redundancy: this is 
an important factor to help reduce the risk of the emer-
gence of escape mutants not covered by the vaccine [9].
Although very important to evaluate potential effective-
ness generated by Bexsero®, MATS is an in vitro test 
which was designed to provide a proxy of the ability of 
Bexsero® to help protect against the diversity of MenB 
subtypes [9]. Of course the results obtained can only be 
used as an indicator of vaccine effectiveness, whereas the 
true vaccine effectiveness will only be available after ex-
tensive use of the vaccine, i.e. in vaccination campaigns. 
However, if countries intend to use currently available 
MATS data, they should be aware that the current estima-
tion obtained by MATS may be an underestimation of the 
true ability of Bexsero® to help protect against circulating 
Men B subtypes for several reasons [5]. In fact MATS 
does not account for the activity of antibodies from non-
PorA OMV antigens nor it can take into account synergis-
tic effects among the multiple vaccine components [21] 
or differential expression of antigens when expressed in 
vivo rather than in vitro: for example NadA expression is 
repressed under in vitro growth conditions used in both 
MATS and hSBA and NHBA expression is temperature-
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regulated and is reduced at 37°C, the temperature at which 
MATS is performed [22, 23].
Recently, a new study aiming at experimentally validating 
the accuracy of MATS predictions tested strains isolated 
from England and Wales between 2007 and 2008 in the 
hSBA assay with pooled sera from infant and adolescent 
vaccinees, and compared these results with MATS. The re-
sults showed that 66% of the strains predicted not covered 
by MATS were killed in the hSBA assay (false negatives). 
Only one of the 28 strains predicted positive by MATS was 
resistant to killing in the hSBA assay. The authors con-
cluded that MATS is a conservative predictor of the strain 
coverage of Bexsero® in infants and adolescents [24]. The 
same conclusion was reached in a second study conducted 
in Spain in which pooled sera from adolescents and infants 
have been tested by hSBA assay against 10 meningococcal 
group B strains that were negative or that had very low lev-
els of the 3 antigens by MATS. It was found that all strains 
were killed by sera from adolescents and that 5 out of 10 
strains were also killed, although at a low titer, by sera from 
infants [25]. 
In the future MATS could be useful in post implementa-
tion programs to monitor the effectiveness and coverage 
of Bexsero® over time [9].
Potential coverage of Bexsero® vaccine 
on non-B meningococci
Bexsero® main antigens are not exclusive to serogroup 
B because the genes encoding for the antigens fHbp, 
NHBA and NadA can be present and expressed also in 
the other serogroups suggesting that the immunization 
with Bexsero® could potentially offer a certain level of 
protection also against non-B strains [12]. Some inves-
tigations have been carried out in order to explore the 
potential impact of MenB vaccination against non sero-
group B disease in different geographic areas (Australia, 
Europe and Brazil) [12, 13, 26]. 
In a study designed to estimate Bexsero® coverage in 
Australia, 108 meningococcal non-B isolates (sero-
groups C [n = 50], W [n = 27], Y [n = 30] and X [n = 1]) 
were tested using MATS. Of the non-B strains tested, 
56% (39-76%) exceeded thresholds for at least one Bex-
sero® antigen [C, 64% (46-86%); W, 63% (41-93%); Y, 
37% (27-43%)]. These preliminary results using MATS 
with non-B strains indicate that non-B strains circulating 
in Australia express significant levels of Bexsero® anti-
gens [26]. However it should be noted that the MATS 
thresholds established for fHbp, NHBA and NadA were 
derived on serogroup B strains and their use to predict 
non-B strain coverage has not yet been validated [9]. 
Due to this, the ability of pooled sera from infants and 
adolescents immunized with Bexsero® to kill meningo-
coccal C, W and Y strains isolated in Europe and Brazil 
has been recently described. In this study, a subpanel of 
147 non-B meningococci isolates, representative of the 
genetic diversity of non B strains isolated in UK, Germa-
ny, France and Brazil, was collected and tested in serum 
bactericidal assay using human complement. The results 
showed that sera of subjects immunized with Bexsero are 
able to induce complement mediated killing of MenC, 
MenW and MenY in a range from 45% to 90%, suggest-
ing that Bexsero® could potentially have an impact on 
meningococcal disease caused by non B serogroups [13]. 
It is noteworthy that the first investigation about the po-
tential ability of Bexsero® to cover non-B serogroups 
meningococci was a pilot evaluation on the possibility of 
controlling the emerging Neisseria meningitidis capsular 
group X causing some recent outbreaks in Africa [27]. 
These preliminary results can represent an indication 
that Bexsero® may potentially have an impact on pre-
vention of the meningococcal disease caused by non B 
serogroups [12, 26, 27].
The UK Joint Committee on Vaccination (JCVI) has 
stated that “the multicomponent MenB vaccine Bexse-
ro® would likely provide some protection against other 
serogroups of meningococci, including serogroup C” 
thus suggesting the possibility to remove the dose of 
meningococcal C vaccine at 3 months of age in the im-
munizations infants calendar, after the introduction of 
MenB vaccine as a universal vaccination for infants in 
the UK schedule [28, 29]. 
Future perspective 
Even if the circulation of N. meningitidis serogroups is 
typically dynamic and diverse in its geographic distribu-
tion, 5 serogroups are accountable for the majority of 
invasive meningococcal disease: A, B, C, Y and W135. 
Since the year 2000 many European states, as well as 
Canada, have experienced substantial declines in the 
incidence of serogroups C disease after the extended 
use of glycoconjugate polysaccharide monovalent sero-
group C vaccine [30, 31]. 
Most recently also tetravalent glycoconjugate vaccines 
including serogroups A,C,W,Y are available to help pre-
vent the disease in Europe, North and Latin America and 
Asia and lastly the first broadly effective MenB vaccine, 
Bexsero®, has been licensed in the EU, USA, Canada, 
Australia, Brazil and Uruguay among other countries for 
various age groups [8, 10]. 
Efforts are currently ongoing to develop a combination 
meningococcal vaccine including antigens against the 5 
meningococcal serogroups: A, B, C, Y and W135 [32, 33].
Investigational formulations of a meningococcal ABCWY 
vaccine, containing oligosaccharides from meningococ-
cal serogroups ACWY conjugated to a CRM197 carrier 
protein, as well as MenB vaccine components, have been 
administered in healthy adolescents in clinical trials in the 
USA and Latin America [32, 33]. Studies results showed 
that the investigational MenABCWY formulations are 
able to elicit a robust immune response against ACWY 
serogroups and serogroup B test strains with an accept-
able reactogenicity and safety profile. If confirmed and 
approved by regulatory agencies, this approach could 
lead to the availability of a pentavalent vaccine capable of 
helping to prevent invasive meningococcal diseases from 
the majority of circulating strains [32, 33].
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With the availability of the existing glyconjugates, the 
protein-based multi-component MenB vaccine and the 
potential pentavalent combination aiming at offering 
protection to human populations against the five major 
serogroups (A, B, C, Y, and W-135), the world might 
reach the milestone of being for the first time ever capa-
ble of preventing the majority of meningococcal menin-
gitis, adding a new chapter in medical history [3].
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